An Analysis for Aggravation of Thyroid Function After Discontinuing Potassium Iodine in Graves’ Patients Treated With Methimazole and Potassium Iodine

Seigo Tachibana, Yusuke Mori, Tadao Yokoi, Shinya Sato, Toshihiko Yanase, Horoyuki Yamashita

Abstract


Background: The efficacy of methimazole (MMI) combined with potassium iodine (KI) therapy as an initial treatment of Graves’ disease (GD) is reported in an area of excessive iodine intake. However, transient aggravation of thyroid function after cessation of KI is often observed. Therefore, we evaluated the factors related with transient aggravation after cessation of KI in GD patients treated with MMI and KI therapy.

Methods: This was a retrospective chart review. Seventy-three GD patients were enrolled in this study. Subjects were divided into two groups. Subjects with transient aggravation were group A, and those without transient aggravation were group B. Between two groups, possible factors were evaluated. Standardized assays were used to measure TSH, free T4 (FT4), free T3 (FT3) and thyrotropin-binding inhibitor immunoglobulin (TRAb). Ultrasonography was used to estimate thyroid volume.

Results: Fisher’s exact test or Mann-Whitney U test revealed that “firstly adjusted drugs”, “the duration of FT4 normalization from initiation of medication to correction of FT4 to normal range” and “adoption of simultaneous reduction of both MMI and KI” are significant factors. In addition, the latter two factors stayed significant even by multiple logistic regression analysis.

Conclusion: Our study suggested that the methods of drugs’ adjustment and “the duration from initiation of medication to normalization of thyroid hormone” may be significant factors of transient aggravation after cessation of KI. It may be better not to reduce both drugs simultaneously, especially in patients who show the relatively shorter duration of normalization of thyroid function.




J Endocrinol Metab. 2013;3(6):132-137
doi: http://dx.doi.org/10.4021/jem204w


Keywords


Graves’ disease; Methimazole; Potassium iodine; Transient aggravation

Full Text: HTML PDF
 

Browse  Journals  

     

Journal of clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 

 

 

 

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.